ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,159,455 | -13.3% | 595,411 | -1.8% | 0.02% | -3.8% |
| Q2 2023 | $18,637,416 | -12.7% | 606,292 | +2.3% | 0.03% | -18.8% |
| Q1 2023 | $21,345,289 | -9.2% | 592,431 | -0.5% | 0.03% | -13.5% |
| Q4 2022 | $23,519,024 | +0.2% | 595,117 | +1.9% | 0.04% | -7.5% |
| Q3 2022 | $23,467,000 | -5.2% | 584,051 | -0.8% | 0.04% | +2.6% |
| Q2 2022 | $24,751,000 | +12.1% | 588,755 | +3.9% | 0.04% | +34.5% |
| Q1 2022 | $22,070,000 | -7.2% | 566,475 | -5.1% | 0.03% | +3.6% |
| Q4 2021 | $23,785,000 | +50.5% | 596,869 | +36.5% | 0.03% | +40.0% |
| Q3 2021 | $15,800,000 | -32.5% | 437,188 | -23.5% | 0.02% | -31.0% |
| Q2 2021 | $23,421,000 | -6.5% | 571,384 | -0.5% | 0.03% | -12.1% |
| Q1 2021 | $25,049,000 | +153.6% | 574,260 | +191.0% | 0.03% | +135.7% |
| Q4 2020 | $9,879,000 | +58.9% | 197,373 | +33.5% | 0.01% | +40.0% |
| Q3 2020 | $6,219,000 | – | 147,831 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |